+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
25 Apr 2015

FDA approves first generic Copaxone to treat multiple sclerosis

The U.S. Food and Drug Administration today approved the first generic version of Copaxone (glatiramer acetate injection), used to treat patients with relapsing forms of multiple sclerosis (MS).

Sandoz has received FDA approval to market generic glatiramer acetate in a 20 mg/1 ml daily injection.

Glatiramer acetate (also known as Copolymer 1, Cop-1, or Copaxone – as marketed by Teva Pharmaceuticals) is an immunomodulator drug currently used to treat multiple sclerosis.

Glatiramer acetate has been approved for marketing in 49 countries worldwide, including the United States, Israel, Canada and 24 European Union Countries.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.